Through the elimination of the SOS1-KRAS protein-protein interaction (PPI), these agents aim to impair the downstream signaling cascades and suppress cancer cell growth in KRAS-driven cancers, for example, colon cancer (CRC) [32,33]. This evidence concerns the gene SOS1 and colorectal carcinoma.